Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
2024-11-13 4:30 pm Purchase | 13G | ADAPTIVE BIOTECHNOLOGIES CORP ADPT | Rubric Capital Management LP | 14,400,000 9.760% | 14,400,000 (New Position) | View |
2024-11-13 09:00 am Sale | 13G | ADAPTIVE BIOTECHNOLOGIES CORP ADPT | Matrix Capital Management Company LP | 650,000 0.440% | -10,922,590 (-94.38%) | View |
2024-11-12 1:30 pm Unchanged | 13G | ADAPTIVE BIOTECHNOLOGIES CORP ADPT | VANGUARD GROUP INC | 10,639,440 7.210% | 0 (Unchanged) | View |
2024-11-08 3:15 pm Purchase | 13G | ADAPTIVE BIOTECHNOLOGIES CORP ADPT | Nikko Asset Management Americas Inc. | 7,733,884 5.240% | 7,733,884 (New Position) | View |
2024-11-05 06:07 am Purchase | 13G | ADAPTIVE BIOTECHNOLOGIES CORP ADPT | Sumitomo Mitsui Trust Group Inc. | 7,733,884 5.240% | 7,733,884 (New Position) | View |
2024-11-04 10:58 am Sale | 13G | ADAPTIVE BIOTECHNOLOGIES CORP ADPT | VANGUARD GROUP INC | 10,639,440 7.210% | -2,128,244 (-16.67%) | View |
2024-10-11 4:14 pm Purchase | 13G | ADAPTIVE BIOTECHNOLOGIES CORP ADPT | INTEGRATED CORE STRATEGIES (US) LLC | 9,400,573 6.400% | 1,650,440 (+21.30%) | View |
2024-05-28 4:22 pm Purchase | 13G | ADAPTIVE BIOTECHNOLOGIES CORP ADPT | INTEGRATED CORE STRATEGIES (US) LLC | 7,750,133 5.300% | 7,750,133 (New Position) | View |
2024-02-14 10:23 am Unchanged | 13G | ADAPTIVE BIOTECHNOLOGIES CORP ADPT | VIKING GLOBAL INVESTORS LP | 29,993,708 20.700% | 0 (Unchanged) | View |
2024-02-13 4:55 pm Purchase | 13G | ADAPTIVE BIOTECHNOLOGIES CORP ADPT | VANGUARD GROUP INC | 12,767,684 8.820% | 973,516 (+8.25%) | View |
2024-01-29 4:00 pm Purchase | 13G | ADAPTIVE BIOTECHNOLOGIES CORP ADPT | ARK Investment Management LLC | 12,806,513 8.850% | 3,605,268 (+39.18%) | View |
2024-01-26 11:49 am Sale | 13G | ADAPTIVE BIOTECHNOLOGIES CORP ADPT | BlackRock Inc. BLK | 11,421,554 7.900% | -952,643 (-7.70%) | View |
2023-02-13 3:52 pm Purchase | 13G | ADAPTIVE BIOTECHNOLOGIES CORP ADPT | BlackRock Inc. BLK | 12,374,197 8.700% | 12,374,197 (New Position) | View |
2023-02-10 10:25 am Purchase | 13G | ADAPTIVE BIOTECHNOLOGIES CORP ADPT | ARK Investment Management LLC | 9,201,245 6.430% | 9,201,245 (New Position) | View |
2023-02-09 10:54 am Purchase | 13G | ADAPTIVE BIOTECHNOLOGIES CORP ADPT | VANGUARD GROUP INC | 11,794,168 8.250% | 762,880 (+6.92%) | View |
2022-09-12 2:07 pm Sale | 13G | ADAPTIVE BIOTECHNOLOGIES CORP ADPT | PRICE T ROWE ASSOCIATES INC | 4,081,518 2.900% | -10,159,096 (-71.34%) | View |
2022-02-14 5:02 pm Unchanged | 13G | ADAPTIVE BIOTECHNOLOGIES CORP ADPT | VIKING GLOBAL INVESTORS LP | 29,993,708 21.300% | 0 (Unchanged) | View |
2022-02-14 12:05 pm Sale | 13G | ADAPTIVE BIOTECHNOLOGIES CORP ADPT | Matrix Capital Management Company LP | 11,572,590 8.200% | -1,542,500 (-11.76%) | View |
2022-02-10 1:16 pm Purchase | 13G | ADAPTIVE BIOTECHNOLOGIES CORP ADPT | PRICE T ROWE ASSOCIATES INC | 14,240,614 10.000% | 953,901 (+7.18%) | View |
2022-02-10 1:13 pm Purchase | 13G | ADAPTIVE BIOTECHNOLOGIES CORP ADPT | PRICE T ROWE ASSOCIATES INC | 13,286,713 9.400% | 13,286,713 (New Position) | View |